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Introduction:  Late recurrence of renal cell carcinoma is rare and mostly of clear cell histology. The objective
of our study was to report our case of late recurrence of papillary RCC.
Observation:  Seventy year old female patient was presented to our department, more than 7 years post
radical nephrectomy for moderate risk RCC. The presentation was persistent localized abdominal pain and
proved by immunohistochemistry to be a metastatic papillary RCC.
Conclusion:  Any symptomatic patient, with history of previous radical nephrectomy, should have recurrent
cancer considered in his differential diagnosis.
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Introduction
Renal cell carcinoma (RCC) is an aggressive but curable disease.
Moderate risk cancer (T2-4 N0) is characterized by up to 70% risk
of early local and metastatic recurrence [1]. Both American urol-
ogy association (AUA) and national comprehensive cancer network
(NCCN) recommend radiological follow up till 5 years post-surgery,
with no specific recommendations for surveillance after that [1,2].
Canadian urology association (CUA) extends radiological follow
up to 6 years [3] while European association of urology (EAU)∗ Corresponding author.
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ecommended surveillance for 3–5 years and left more prolonged
urveillance option for clinician’s judgement [4]. Median time to
elapse has been reported to be within less than 3 years and lungs
ave been reported to be the most common site of recurrence [5–7].
he aim of our study was to report a rare case of late retroperitoneal
etastasis of a moderate risk papillary RCC.
ase  report
eventy year old female patient presented with left iliac dull aching
ain, not responding to non-steroidal anti-inflammatory drugs. The
atient had left radical nephrectomy in 2010 for large complicated
yst in the left kidney and pathology came back as papillary RCC
tage 1. The patient was followed by annual C.T. for 5 years, and then
nd hosting by Elsevier B.V. This is an open access article under the CC



























Figure  1  Axial C.T. images, 
ischarged from urology care with no evidence of local or systemic
pread.
ecause of the persistent pain, C.T. scan was requested that showed
o tumour recurrence in renal bed and an enhancing mass in the
eft iliac region (Figs. 1 and 2). C.T. guided biopsy was done and
athology came back as an anaplastic carcinoma.
fter discussion in tumour board, decision was made to proceed with
urgical open exploration and mass excision. The mass was well
ircumscribed measuring 8.5 ×  6.5 ×  3 cm3. Cytokeratin 7 (CK7),
luster of differentiation 10 (CD10) and Wilms’ tumour 1 (WT1)
ere studied and came back negative, initially excluding renal cell
arcinoma. Alpha methylacyl Co A racemase (AMACR) immunos-
aining was then done and came back positive, suggesting the




Figure  2  Coronal C.T. images, showing an enhanced left iliac mass.
iscussion
ark et al. studied 747 patients that had radical nephrectomy and
btained follow up studies for more than 5 years. He found that late
ecurrence (>5 years) happened in 5% of the patients. Interestingly;
o single patient with late recurrence had papillary histology and
7% of the patients had clear cell histology [8]. Miyao et al. studied
ate recurrence on 470 patients and confirmed that it happened in
% of patients, but the study did not refer to the histological subtype
f the recurrence [9]. Interestingly; both studies [8,9] found that the
ajority of late recurrence, in agreement with our case, happened
n cases that had stage 1 renal tumour on first surgery. Kuchar-
zyk and Matrana studied 720 patients that had radical nephrectomy
nd found that 100% of late recurrence was clear cell histology
10].





Late recurrent RCC 
Our patient had a smooth recovery from surgery and was enrolled
back into surveillance C.T. scan. She was assured that she is likely
to have good survival based on having a solitary abdominal recur-
rence that was completely removed more than 5 years after surgery.
Kavolius et al. [11] conducted a retrospective study on 278 patients
that developed recurrence post radical nephrectomy and found that
favorable survival outcomes were obtained for patients with long
disease free survival before recurrence and patients with solitary
recurrence that was completely resected. Another study conducted
on 256 patients with recurrence concluded that late recurrence and
favorable Memorial Sloan-Kettering Cancer Center risk score can
predict good survival following metastatectomy [12]. Margulis et al.
[13] studied 54 patients with recurrence and found that some bio-
chemical and pathological factors may play roles as prognostic
markers for survival, but the mainstay for favorable cancer specific
survival is the aggressive resection of the metastasis.
Conclusion
Any symptomatic patient, with history of previous radical nephrec-
tomy, should have recurrent cancer considered in his differential
diagnosis.
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